Demographic characteristics of patients
After performing WES or CES, 39 IEI patients with mutations in DNA repair and methylation genes were recruited for this study. According to molecular diagnosis, we divided our patients into two groups, including atypical SCID (n = 3; DCLRE1C- OMIM #602450) (n = 1), DNA-PRKDC-OMIM #615966 (n = 1), DNA ligase-4-OMIM #606593 (n = 1), and combined immunodeficiency with DNA repair defects with syndromic features (n = 36; Bloom syndrome-OMIM # 210900 (n = 1), AT-OMIM #208900 (n = 35)). (Fig. 1A, Table 1).
Table 1
Clinical and demographic features of the patients.
Patient | Subgroup | Genetic Defect | Gender, Age (mo) | Age at diagnosis (mo) | Age at onset | Infections | Other clinical findings | Treatment |
P1 | AT | ATM p.Vol1506*(c.4514delC) | F, 90 | 31 | 18 | None | Ataxia, NDD, Short stature (+) | IgRT sc |
P2 | AT | ATM (c.6047A > G, P.Asp2016Gly) | F, 176 | 53 | 6 | Rec RTI, Candida albicans (+) | NDD, Short stature | IgRT sc; Azithromycin and TMP-SMZ px |
P3 | AT | ATM (c.6047A > G, P.Asp2016Gly) | F, 74 | 18 | 18 | None | Lymphadenopathy, NDD, Short stature | IgRT sc, Azithromycin px |
P4 | AT | ATM p.Phe2387(c.7159-7160insAGCC) | F, 120 | 24 | 64 | Rec RTI, Rec Otitis media and sinusitis | Factor 11 deficiency, Bronchiolitis obliterans, Atopic dermatitis, NDD, Short stature | IgRT sc |
P5 | AT | ATM p.Phe2387(c.7159-7160insAGCC) | F, 39 | 6 | 13 | None | Congenital hypothyroidism, NDD | IgRT sc |
P6 | AT | ATM p.A2622V (c.7865C > T) | M, 162 | 72 | 18 | None | Febrile convulsion, NDD, Short stature | None |
P7 | AT | ATM p.K1192K (c.3576G > A) | M, 171 | 143 | 18 | Rec RTI and diarrhea | Alopecia, Dystonia, Scoliosis, Enuresis, Encopresis, NDD, Short stature | IgRT IV |
P8 | AT | ATM p.Glu2014(c.6040G > T) | F, 58 | 24 | 18 | Rec RTI (S. Pneumoniae +), Urinary tract infections, moniliasis | Autoimmune hemolytic anemia, Hepatosplenomegaly, Lymphadenopathy, Protein-losing enteropathy, NDD, Short stature, arterial aneurysm, Congenital hypothyroidism | IgRT sc |
P9 | AT | ATM c.B050 C > T (p. Gln2684*) | M,92 | 25 | 10 | Rec RTI | NDD, Short stature | IgRT IV, Azithromycin and TMP-SMZ px |
P10 | AT | ATM c.3576G > A (p.K1192) | M, 134 | 84 | 60 | None | NDD | TMP-SMZ px |
P11 | AT | ATM c.6701T > c (p.L2234P) (novel) | M, 162 | 119 | 14 | Rec Otitis media and sinusitis | NDD | IgRT IV; Azithromycin and TMP-SMZ px |
P12 | AT | ATM p.Arg.35 (c.103C > T) heterozygous, (c.2251-4A > G) heterozygous | F, 225 | 72 | 48 | Herpes Zoster | Non-Hodgkin's lymphoma | None |
P13 | AT | ATM c.6046G > p.Asp2016Tyr | M, 183 | 162 | 18 | Rec Otitis media | Atopic dermatitis, Dysmorphic face | IgRT IV and TMP-SMZ px |
P14 | AT | ATM p.Gln852*(c.2554 > T) | F, 80 | 47 | 12 | Rec Otitis media, Septic arthritis | Granuloma at skin, Dysmorphic face, Hepatosplenomegaly, Lymphadenopathy, NDD, Short stature | IgRT IV, TMP-SMZ px, hydroxychloroquine |
P15 | AT | ATM c.4973delC | M, 63 | 25 | 13 | Rec sinusitis, Atelectasis in thorax CT | Dysmorphic face, Hepatomegaly, T cell leukemia, Chronic diarrhea, NDD, Short stature | IgRT IV, Voriconazole and 6-MP |
P16 | AT | ATM c.3576G > A, p.Lys1192= | F, 114 | 73 | 13 | None | Atopic dermatitis, Dysmorphic face, NDD | None |
P17 | AT | ATM c.6583_6584delCA (p.H2195X) | F, 111 | 54 | 11 | Rec RTI, Urinary tract infections | Dysmorphic face, NDD, Short stature | Azithromycin px |
P18 | AT | ATM c.3576G > A, p.Lys1192= | F, 124 | 103 | 18 | None | NDD | TMP-SMZ px |
P19 | AT | ATM c.8122 G > A (p.Asp2708Asn) heterozygous, c.8024_8026delGAG (p.Gly2675del)heterozygous | F, 93 | 72 | 15 | None | Epilepsy, Short stature | None |
P20 | AT | ATM c.3802delG (p. Val1268Terfs) | M, 110 | 73 | 14 | Rec RTI, sinusitis and diarrhea | Nephrolithiasis, Dismorphic face, Cleft lip and palate, NDD, Short stature | TMP-SMZ px |
P21 | AT | ATM c.4973delC c.4973delC | M, 91 | 27 | 12 | Rec RTI | Dismorphic face, Autoimmun thyroiditis, Short stature | IgRT IV and TMP-SMZ px |
P22 | AT | ATM c.2921 + 1G > A | M, 62 | 30 | 15 | Rec Otitis media and sinusitis | NDD | None |
P23 | AT | ATM c.7788G > A (p.Glu2596=) | M, 101 | 18 | 12 | None | NDD | None |
P24 | AT | ATM c.3576G > A (p.Lys1192=) | F, 37 | 36 | 24 | None | NDD, Vitiligo | None |
P25 | AT | ATM c.3576G > A (p.Lys1192=) | M, 97 | 96 | 24 | None | NDD, Vitiligo | None |
P26 | AT | N/A | F, 42 | 40 | 21 | None | None | IgRT IV |
P27 | AT | ATM c.2284_2285delCT (p.Leu762ValfsTer2) | M, 57 | 52 | 12 | Rec RTI | None | IgRT IV |
P28 | AT | ATM c.756_757delTG(p.Cys252*) heterozygous/ c.7865C > T(p.Ala2622Val) heterozygous | M, 65 | 41 | 24 | Rec RTI (S. Pneumoniae, H. İnfluenza, Rhinovirus,Parainfluenza virus) | Lymphadenopathy, Short stature | IgRT IV |
P29 | AT | ATM c.756_757delTG(p.Cys252*) heterozygous/ c.7865C > T(p.Ala2622Val) heterozygous | F, 29 | 12 | 12 | Rec RTI (S. Pneumoniae, H. İnfluenza, Rhinovirus,Parainfluenza virus) | None | IgRT IV |
P30 | AT | ATM p.Glu2596=(c.7788G > A) | F, 137 | 91 | 60 | Rec RTI, Rec Otitis media and sinusitis, Oral moniliasis, Persistent fever | NDD, Short stature, Corneal punctuate epitheliopathy, Febrile seizure | IgRT IV |
P31 | AT | ATM p.Asp2016Gly (c.6047A > G) | F, 153 | 82 | 72 | Persistent fever, Rec RTI | Lymphadenopathy, NDD, Short stature, Bronchiectasis | IgRT IV |
P32 | AT | N/A | F, 69 | 15 | 13 | Rec RTI (S. Pneumoniae, H. İnfluenza, Adenovirus) | Short stature, Bronchiectasis | IgRT IV |
P33 | AT | ATM p.Glu2596Glu (c.7788G > A) | F, 115 | 63 | 24 | None | Dismorphic face, NDD, Short stature, WPW Syndrome | None |
P34 | AT | ATM p.Glu2596Glu (c.7788G > A) | F, 80 | 54 | 12 | None | NDD, Short stature | None |
P35 | AT | ATM p.Glu2596Glu (c.7788G > A) | F, 61 | 36 | 12 | None | NDD, Short stature | None |
P36 | Bloom Syndrome | BLM chr15.91346925, c.3535del (p.Thr1179LeufsTer3) | M, 132 | 125 | 1 | Rec RTI | Dismorphic face, Short stature, Hyperpigmented macules | IgRT IV |
P37 | DNA PRKDC Deficiency | PRKDC c.10423_10426dup (p.Glu3476Alafs*48) heterozygous, c.7783C > T p(Arg2595Cys) heterozygous | F, 53 | 46 | 37 | Rec diarrhea and recurrent abscess, Oral moniliasis | Anal fistula, Inflammatory bowel disease like symptoms, Dysmorphic face, Lymphadenopathy, Sclerosing cholangitis, NDD, Short stature | IgRT IV |
P38 | Artemis Deficiency | DCLRE1C c.632G > T homozygous | M, 85 | 83 | 77 | Rec RTI | Bronchiectasis | IgRT IV and TMP-SMZ px |
P39 | DNA Ligase 4 Deficiency | LIG4 c833G > A, p.Arg278His, c.724_725delTT, p.Leu242llefsTer5 compound heterozygous | M, 221 | | 18 | Rec RTI and Otitis media, persistent fever | Atopic dermatitis, Dysmorphic face, NDD, Short Stature, Vitiligo, Epilepsy, Microcephaly | IgRT IV and TMP-SMZ px |
ATM: Ataxia telangiectasia mutated |
RTI: respiratory tract infections |
NDD: neurodevelopmental delay |
IgRT: Immunoglobuline replacement therapy |
Px: prophylaxis |
TMP-SMZ: trimethoprim sulfamethoxazole |
WPW: Wolf Parkinson White |
A total of 39 patients (n = 17 (43.5%) males and n = 22 (56.5%) females) with a median age of 93 months (IQR 25–75: 63–134 months) were included. Thirty-one (79.5%) of all patients were from a blood-related family. The median age of all patients at symptom onset was 18 months (IQR 25th-75th: 12–24 months), and the median age at diagnosis was 54 months (IQR 25th-75th: 30–82 months). The median duration of diagnostic delay was 31 months in all groups (IQR 25th-75th: 12–57 months), and it was shorter in AT patients (36.8 months) than in the others (88.5 months). However, these differences were not statistically significant (p = 0.110).
Clinical Findings and Immunological Results of Patients
Clinical findings of the patients are given in Table 1, Fig. 1B and Table S1.
Immunological work-up revealed absolute T-cell, B-cell and total CD4 + and CD8 + T cell counts which is consistent with previous studies, only T-cell and CD4 + T-cell counts were lower than in previous studies.7,21,33 The immunological parameters are given in Table S2, Table S3 and Fig S1.
Oligoclonality of the TCR repertoire and correlation with clinical phenotype
In general, TCR repertoires are thought to be dynamically variable, with diversity decreasing with age34. Therefore, previous studies have included age-matched controls7,21. When analyzing the TCR-β repertoire in patients with different pathogenic backgrounds, we also included 15 age-matched healthy controls to compare the diversity and complexity of the repertoire.
Overall, the entire TCR-vβ repertoire was detected in all patients. However, compared with the control group, 9 of 24 clones (37.5%) were statistically significantly lower, whereas only 3 clones had high levels (p < 0.05). In addition, 62.5% of all clones had lower values than the control group (Figs. 2 and 3).
The statistically significantly lower clones were TCR-Vβ 7.1(p < 0,01 p = 0,006), Vβ3 (p = 0.01), Vβ9 (p < 0,01 p = 0,005), Vβ17 (p < 0,01 p = 0,009), Vβ2 (p = 0), Vβ22(p < 0,05 p = 0,021), Vβ21.3 (p < 0,01 p = 0,005), Vβ11(p < 0,01 p = 0,004), and Vβ4 (p = 0). And the statistically significant higher clones were TCR-Vβ-20 (p < 0,01, p = 0,004), Vβ12 (p < 0,01 p = 0,004), Vβ14 (p < 0,05 p = 0,037)(Fig. 2).
In other words, the TCR-vβ repertoire of AT patients showed limited diversity compared to healthy controls (HC). Richness is measured by the number of unique TCRs in a given sample. Evenness indicates how evenly distributed the frequencies of each unique TCR are in the estimated population. Shannon entropy considers both richness and evenness to measure diversity. In our study, restriction by low Shannon's H-index (p < 0.05 p = 0,019) and the evenness of clonality by higher Gini coefficient (p < 0.05 p = 0.008; Figs. 4A and 4B) confirmed. This situation predisposed to oligoclonality. These results were also true for all patient groups compared to HC (Shannon's H index (p < 0,05 p = 0.012) and Gini coefficient (p < 0.01 p = 0.002)). When comparing atypical SCID and healthy controls, repertoire diversity using the Shannon H index and evenness of clonality using the Gini coefficient were not statistically evaluated because only 3 patients had atypical SCID.
In addition, some unique Vβ clones have been associated with some clinical entities. Clonotypes associated with infections, autoimmunity and lymphoid proliferation were detected in the patient group. Lower TCR-vβ-9 and TCR-vβ23, higher TCR-vβ7.2 were detected in the patients with pneumonia (n = 13) (respectively p = 0.018, p = 0.044 p = 0.032, Fig. 5A1). In addition, AT patients with pneumonia (n = 10) had a lower TCR-vβ-9 clone than patients without pneumonia (n = 25) (p = 0.008; Fig. 5A2).
Moreover, some additional clones, including TCR-vβ23, TCR-vβ21.3, TCR-vβ22, and TCR-vβ13.2, were associated with chest imaging findings (TFI; consolidation, atelectasis, bronchiectasis, pulmonary nodules; n = 10) and were observed in lower frequency in patients with TFI (Fig. 5B1). As expected, the Gini coefficient indicated heterogeneity of the repertoire and was significantly higher compared to patients without findings in the chest radiograph (p = 0.041, Fig. 4C). When comparing TFI (+) AT patients (n = 8) and TFI (-) AT patients (n = 27), TCR-vβ11 and TCR-vβ5.2 were significantly lower in the AT group with TFI than when comparing HC and all patients (p = 0.023 and p = 0.039, respectively) (Fig. 5B2).
The number of patients with bronchiectasis was too small to compare statistically, but clones with similar statistical significance to patients with thorax findings in imaging were detected as possibly associated with pulmonary pathologies (Fig. 5C). The Gini coefficient was also higher than in patients without bronchiectasis (p = 0.024, fig. S3). In addition, sinusitis (n = 6) and otitis media (OM, n = 7) were also associated with some clones. However, their statistical significance was limited (Fig. 5D1). Moreover, the same TCR-vβ clone was significantly lower than in the patients with OM, when comparing AT patients with and without OM (Fig. 5D2). The oligoclonality could be attributed to recurrent or chronic infections causing selective expansion of some clones.
The patients with lymphoproliferation (lymphadenopathy and/or hepatosplenomegaly, n = 9) had some distribution abnormalities, including TCR-vβ2 higher than in the lymphoproliferative patient group (p = 0.041, Fig. 6). Expansions of TCR-vβ9, TCR-vβ5.1, TCR-vβ22, and TCR-vβ14 were detected in two patients affected by malignancy (T-cell leukemia, n = 1 and non-Hodgkin's lymphoma, n = 1, respectively p < 0.001, p = 0.009, p = 0.009, p = 0.013).
Distribution abnormalities, including clonal expansion of TCR-vβ4 and TCR-vβ2 and clonal decrease of TCR-vβ11 and TCR-vβ5.1, were shown in patients with autoimmunity (n = 4, respectively p = 0.033, p = 0.026, p = 0.012, p = 0.044, Fig. 5E1). TCR-vβ4, TCR-vβ11 and TCR-vβ5.1 showed the same pattern when comparing AT patients with (n = 4) and without autoimmunity (n = 31) (respectively p = 0.038, p = 0.007 p = 0.028; Fig. 5E2). Consequently, we suggest that the TCR-vβ repertoire in DNA repair defects, especially in AT patients, is biased by either underutilization or oligoclonal expansion of most vβ families.
Restriction of TCR repertoire and correlation with immunological phenotype
We found that some immunological parameters were significantly associated with certain Vβ clones. CD4 + T-cell lymphopenia was associated with decreased TCR-vβ5.3 and TCR-vβ11 (p = 0.042, p = 0.012, respectively, Fig. 7A). CD8 + T-cell lymphopenia showed an association with decreased TCR-vβ18 (p = 0, Fig. 7B). The same pattern was seen when compared within AT patients.
In addition, TCR-vβ11 levels showed a weak positive correlation with the number of CD4 + T cells (Pearson correlation analysis, r = 0.347), and TCR-vβ7.1 levels also showed a weak positive correlation with the number of CD8 + T cells (Pearson correlation analysis, r = 0.386), but not statistically significant with a group of CD8 + lymphopenic compared to a group of normal CD8 + T cells. This abnormal distribution may predict normal levels of CD4 + T cells and CD8 + T cells correlate with a normal TCR repertoire.